Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
Source: ClinicalTrials.gov NCT04632641 ↗Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Achieve Hemostasis |
7; 11 | — |
| PRIMARY Time to Ambulate |
322; 403 | — |
| SECONDARY Time to Discharge (TTD)/Length of Stay (LOS) |
1257; 1338 | — |
| SECONDARY Post Procedure Major Bleeding |
0; 0 | — |
| SECONDARY Minor Bleeding |
5; 4 | — |
| SECONDARY Access Site Complications |
0; 2 | — |
| SECONDARY Mortality |
0; 0 | — |
Eligibility Criteria
Inclusion criteria
Large-bore (>13F) Venous Access Procedures Inclusion Criteria:
All patients 18 years and older who are undergoing any of the following: WATCHMAN® device placement, atrial fibrillation ablation using cryoballoon or laser balloon, leadless pacemaker, Pulmonary embolism thrombectomy (Inari FlowTriever system), MitraClip transcatheter mitral valve repair at Aurora St. Luke's Medical Center from date of IRB (Institutional Review Board) approval through December 2022. All arterial line access should be radial.
Exclusion criteria
Large-bore (>13F) Venous Access Procedures Exclusion Criteria:
- Patients in whom introducer sheaths >25F were used in the vein during the catheterization procedure.
- Patients with small femoral arteries or veins ( 40 kg/m2) or underweight (BMI < 20 kg/m2)
Data sourced from ClinicalTrials.gov (NCT04632641). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.